Thiel, U. and Wawer, A. and Wolf, P. and Badoglio, M. and Santucci, A. and Klingebiel, T. and Basu, O. and Borkhardt, A. and Laws, H. -J. and Kodera, Y. and Yoshimi, A. and Peters, C. and Ladenstein, R. and Pession, A. and Prete, A. and Urban, E. -C. and Schwinger, W. and Bordigoni, P. and Salmon, A. and Diaz, M. A. and Afanasyev, B. and Lisukov, I. and Morozova, E. and Toren, A. and Bielorai, B. and Korsakas, J. and Fagioli, F. and Caselli, D. and Ehninger, G. and Gruhn, B. and Dirksen, U. and Abdel-Rahman, F. and Aglietta, M. and Mastrodicasa, E. and Torrent, M. and Corradini, P. and Demeocq, F. and Dini, G. and Dreger, P. and Eyrich, M. and Gozdzik, J. and Guilhot, F. and Holler, E. and Koscielniak, E. and Messina, C. and Nachbaur, D. and Sabbatini, R. and Oldani, E. and Ottinger, H. and Ozsahin, H. and Schots, R. and Siena, S. and Stein, J. and Sufliarska, S. and Unal, A. and Ussowicz, M. and Schneider, P. and Woessmann, W. and Juergens, H. and Bregni, M. and Burdach, S. (2011) No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. ANNALS OF ONCOLOGY, 22 (7). pp. 1614-1621. ISSN 0923-7534, 1569-8041
Full text not available from this repository. (Request a copy)Abstract
Background: Outcomes of Ewing tumor (ET) patients treated with allogeneic stem cell transplantation (allo-SCT) were compared regarding the use of reduced-intensity conditioning (RIC) and high-intensity conditioning (HIC) regimens as well as human leukocyte antigen (HLA)-matched and HLA-mismatched grafts. Patients and methods: We retrospectively analyzed data of 87 ET patients from the European Group for Blood and Marrow Transplantation, Pediatric Registry for Stem Cell Transplantations, Asia Pacific Blood and Marrow Transplantation and MetaEICESS registries treated with allo-SCT. Fifty patients received RIC (group A) and 37 patients received HIC (group B). Twenty-four patients received HLA-mismatched grafts and 63 received HLA-matched grafts. Results: Median overall survival was 7.9 months [+/- 1.24, 95% confidence interval (CI) 5.44-10.31] for group A and 4.4 months (+/- 1.06, 95% CI 2.29-6.43) for group B patients (P = 1.3). Death of complications (DOC) occurred in 4 of 50 (0.08) and death of disease (DOD) in 33 of 50 (0.66) group A and in 16 of 37 (0.43) and 17 of 37 (0.46) group B patients, respectively. DOC incidence was decreased (P < 0.01) and DOD/relapse increased (P < 0.01) in group A compared with group B. HLA mismatch was not generally associated with graft-versus-Ewing tumor effect (GvETE). Conclusions: There was no improvement of survival with RIC compared with HIC due to increased DOD/relapse incidence after RIC despite less DOC incidence. This implicates general absence of a clinically relevant GvETE with current protocols.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PERIPHERAL NEUROECTODERMAL TUMORS; TOTAL-BODY IRRADIATION; HIGH-DOSE THERAPY; EUROPEAN INTERGROUP; SARCOMA; BONE; MARROW; GRAFT; TRANSLOCATION; METASTASES; advanced-stage Ewing tumor; allogeneic stem cell transplantation; graft versus tumor effect; haploidentical stem cell transplantation; reduced; high-intensity conditioning chemotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 08 Jun 2020 11:46 |
| Last Modified: | 08 Jun 2020 11:46 |
| URI: | https://pred.uni-regensburg.de/id/eprint/20608 |
Actions (login required)
 |
View Item |
